Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
Antonia DavidsonDarin BrimhallJonathan KayEdward KeystoneSang Joon LeeSung Hyun KimYun Ju BaeEun Jin ChoiDaniel E FurstPublished in: British journal of clinical pharmacology (2021)
CT-P17 AI and CT-P17 PFS were pharmacokinetically equivalent. Overall safety and immunogenicity were comparable between the 2 delivery devices.